Anavex Life Sciences Corp.
NASDAQ:AVXLBiotechnology
-$0.04 today
- Market cap
- $66.69M
- Beta
- 1.12
- P/E (TTM)
- -5.9
- EPS (TTM)
- -$0.45
Volume 1.06M
Average 1.39M
AVXL EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Anavex Life Sciences Corp.NASDAQ: AVXL
EBITDA · Q1 FY2026 · quarter ended Dec 2025
EBITDA remains negative
Q1 FY2026 EBITDA was -$5.66M, compared with -$13.58M a year earlier. Trailing-twelve-month EBITDA was -$38.87M.
Context
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of $0 (+100.0%) for the fiscal year ending Sep 2026, a step up from the -7.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -$5.66M+12.7% QoQ
- Last fiscal yearSep 2025
- -$46.38M-7.8% YoY
- LTMDec 2025
- -$38.87M+24.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +58.3% | +100.0% | +41.7 pp |
| 1 year | -7.8% | +100.0% | +107.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (46.38M) USD
- Year-over-year change
- -7.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | (46.38M) | -7.8% |
| FY2024 | 2024-09-30 | (43M) | +7.6% |
| FY2023 | 2023-09-30 | (46.54M) | +2.3% |
| FY2022 | 2022-09-30 | (47.62M) | -26.5% |
| FY2021 | 2021-09-30 | (37.64M) | — |
EBITDA vs competitors
How AVXL compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +24.6% is the 2nd highest of 10, against a peer median of -87.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | -$38.87M USD | +24.6% | — | — | |
| LTM Mar 2026 | -$57.67M USD | -232.5% | — | 162.2% | |
| LTM Mar 2026 | -€90.14M EUR | -119.6% | — | 57.7% | |
| LTM Mar 2026 | -$95.72M USD | +32.5% | — | 120.0% | |
| LTM Mar 2026 | -$106.84M USD | -14.3% | — | 5818.9% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | -$148.59M USD | -85.2% | — | — |
| LTM Mar 2026 | -$216.5M USD | -437.2% | — | 242.2% | |
| LTM Mar 2026 | -$229.35M USD | -87.3% | — | 261.2% | |
| LTM Mar 2026 | -$245.81M USD | -69.1% | — | — | |
| LTM Sep 2026 | -$305.05M USD | -151.6% | — | — | |
| Peer median (excluding AVXL) | — | -87.3% | — | 202.2% | |
Competitors are the stored peer set for AVXL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.98M | 37.92M | 43.72M | 41.84M | 37.59M |
| Selling, General & Admin | 9.02M | 13.07M | 12.05M | 11.04M | 13.82M |
| Operating Expenses | 42M | 50.99M | 55.76M | 52.88M | 51.41M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (37.64M) | (47.62M) | (46.54M) | (43M) | (46.38M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (42M) | (50.99M) | (55.76M) | (52.88M) | (51.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 26K | 947K | 6.52M | 7.32M | 4.68M |
| Interest Expense | 0 | 0 | 964K | 0 | 0 |
| Other Income / Expenses | 4.36M | 3.37M | 8.26M | 9.88M | 5.03M |
| Income Before Tax | (37.64M) | (47.62M) | (47.51M) | (43M) | (46.38M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 268K | 358K | 0 | 0 | 0 |
| Net Income | (37.91M) | (47.98M) | (47.51M) | (43M) | (46.38M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.54) | (0.62) | (0.60) | (0.52) | (0.54) |
| EPS (Diluted) | (0.54) | (0.62) | (0.60) | (0.52) | (0.54) |
| Weighted Avg Shares | 69.8M | 76.91M | 79.79M | 83.47M | 85.29M |
| Weighted Avg Shares (Diluted) | 69.8M | 76.91M | 79.79M | 83.47M | 85.29M |
Anavex Life Sciences Corp.
NASDAQ:AVXL
Intrinsic Alpha fair value
Locked
Current Price
$0.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.